Advances on the hematopoietic stem cell transplantation for the treatment of multiple myeloma
10.3760/cma.j.issn.1009-9921.2012.08.018
- VernacularTitle:造血干细胞移植治疗多发性骨髓瘤的研究进展
- Author:
Chuanying GENG
- Publication Type:Journal Article
- Keywords:
Multiple myeloma;
Hematopoietic stem cell transplantation
- From:
Journal of Leukemia & Lymphoma
2012;21(8):500-503
- CountryChina
- Language:Chinese
-
Abstract:
Hematopoietic cell transplantation is frontline treatment of multiple myeloma (MM).Autologous hematopoietic stem cell transplantation (auto-HSCT) could improve remission rate,prolong survival time,the tandem auto-HSCT is able to make patients get further benefits for patients not achieving at least very good partial remission after the first auto-HSCT.Allologous hematopoietic stem cell transplantation (alloHSCT) is potentially able to cure multiple myeloma,but patients achieve less benefit because of high transplant-related mortality (TRM).The TRM is low after reduced-intensity conditioning allo-HSCT,but which exhibit no survival benefit.Moreover,patients achieve no survival benefit after tandem auto-HSCT and allologous reduced-intensity conditioning transplantation.This paper reviewes recent studies about HSCT in MM.